Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer
Journal of Clinical Medicine · 21.03.2023 · 12 (6) · 2412
DOI: 10.3390/jcm12062412 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.03.2023. Verfasst von Klaudia Katarzyna Brogowska und 2 weiteren Autor:innen. Beteiligte Einrichtung: Public Health Care Hospital in Knyszyn, 19-120 Knyszyn, Poland. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Białystok, Medical University of Bialystok, Poland.
Abstract (Originalsprache)
Breast cancer (BC) is the most common malignancy responsible for the largest number of deaths in women worldwide. The risk of developing BC is predisposed by many factors such as age, presence of genetic mutations or body weight. The diagnosis is mostly made relatively late, which is why patients are exposed to radical surgical treatments, long-term chemotherapy and lower survival rates. There are no sufficiently sensitive and specific screening tests; therefore, researchers are still looking for new diagnostic biomarkers that would indicate the appearance of neoplastic changes in the initial stage of neoplasm. The VEGF family of proteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D, EG-VEGF, PlGF) and their receptors are significant factors in the pathogenesis of BC. They play a significant role in the process of angiogenesis and lymphangiogenesis in both physiological and pathological conditions. The usefulness of these proteins as potential diagnostic biomarkers has been initially proven. Moreover, the blockage of VEGF-related pathways seems to be a valid therapeutic target. Recent studies have tried to describe novel strategies, including targeting pericytes, use of miRNAs and extracellular tumor-associated vesicles, immunotherapeutic drugs and nanotechnology. This indicates their possible contribution to the formation of breast cancer and their usefulness as potential biomarkers and therapeutic targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Public Health Care Hospital in Knyszyn, 19-120 Knyszyn, Poland.
- Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
- Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.
ORCID-Profile: Monika Zajkowska
Förderung
- Medical University of Białystok
- Medical University of Bialystok, Poland
Zitieren
APA
Brogowska, K. K., Zajkowska, M., & Mroczko, B. (2023). Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer. Journal of Clinical Medicine, 12(6), 2412. https://doi.org/10.3390/jcm12062412
Vancouver
Brogowska KK, Zajkowska M, Mroczko B. Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer. Journal of Clinical Medicine. 2023;12(6):2412. doi:10.3390/jcm12062412
BibTeX
@article{Brogowska2023,
author = {Brogowska, Klaudia Katarzyna and Zajkowska, Monika and Mroczko, Barbara},
title = {Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {6},
pages = {2412},
doi = {10.3390/jcm12062412}
}
EUVIMED